These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 31894448)
1. PDGFRβ-targeted TRAIL specifically induces apoptosis of activated hepatic stellate cells and ameliorates liver fibrosis. Li R; Li Z; Feng Y; Yang H; Shi Q; Tao Z; Cheng J; Lu X Apoptosis; 2020 Feb; 25(1-2):105-119. PubMed ID: 31894448 [TBL] [Abstract][Full Text] [Related]
2. Targeted Delivery to Tumor-associated Pericytes via an Affibody with High Affinity for PDGFRβ Enhances the Tao Z; Yang H; Shi Q; Fan Q; Wan L; Lu X Theranostics; 2017; 7(8):2261-2276. PubMed ID: 28740549 [TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor receptor β-targeted positron emission tomography imaging for the noninvasive monitoring of liver fibrosis. Li Z; Yang H; Li X; She T; Tao Z; Zhong Y; Su T; Feng Y; Shi Q; Li L; Tian R; Wang S; Cheng J; Cai H; Lu X Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1530-1543. PubMed ID: 38189910 [TBL] [Abstract][Full Text] [Related]
4. Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells. Oh Y; Park O; Swierczewska M; Hamilton JP; Park JS; Kim TH; Lim SM; Eom H; Jo DG; Lee CE; Kechrid R; Mastorakos P; Zhang C; Hahn SK; Jeon OC; Byun Y; Kim K; Hanes J; Lee KC; Pomper MG; Gao B; Lee S Hepatology; 2016 Jul; 64(1):209-23. PubMed ID: 26710118 [TBL] [Abstract][Full Text] [Related]
5. Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo. Li Q; Ding Y; Guo X; Luo S; Zhuang H; Zhou J; Xu N; Yan Z J Cell Mol Med; 2019 Mar; 23(3):1951-1962. PubMed ID: 30592139 [TBL] [Abstract][Full Text] [Related]
6. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708 [TBL] [Abstract][Full Text] [Related]
7. Targeting delivery of a novel TGF-β type I receptor-mimicking peptide to activated hepatic stellate cells for liver fibrosis therapy via inhibiting the TGF-β1/Smad and p38 MAPK signaling pathways. Liu X; Wang X; Xu L; Fan J; Yuan Q; Zhang F; Liu J; Qiu X; Li Y; Xia C; Liu H Eur J Pharmacol; 2024 Aug; 977():176708. PubMed ID: 38843945 [TBL] [Abstract][Full Text] [Related]
8. Taurine attenuates activation of hepatic stellate cells by inhibiting autophagy and inducing ferroptosis. Li S; Ren QJ; Xie CH; Cui Y; Xu LT; Wang YD; Li S; Liang XQ; Wen B; Liang MK; Zhao XF World J Gastroenterol; 2024 Apr; 30(15):2143-2154. PubMed ID: 38681990 [TBL] [Abstract][Full Text] [Related]
9. Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells. Arabpour M; Cool RH; Faber KN; Quax WJ; Haisma HJ J Drug Target; 2017 Apr; 25(4):360-369. PubMed ID: 27885847 [TBL] [Abstract][Full Text] [Related]
10. PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer. Shi Q; Tao Z; Yang H; Fan Q; Wei D; Wan L; Lu X Drug Deliv; 2017 Nov; 24(1):1818-1830. PubMed ID: 29182023 [TBL] [Abstract][Full Text] [Related]
11. CREKA-modified liposomes target activated hepatic stellate cells to alleviate liver fibrosis by inhibiting collagen synthesis and angiogenesis. Li R; Zhang J; Liu Q; Tang Q; Jia Q; Xiong Y; He J; Li Y Acta Biomater; 2023 Sep; 168():484-496. PubMed ID: 37392933 [TBL] [Abstract][Full Text] [Related]
12. Liver fibrosis therapy based on biomimetic nanoparticles which deplete activated hepatic stellate cells. Xia S; Liu Z; Cai J; Ren H; Li Q; Zhang H; Yue J; Zhou Q; Zhou T; Wang L; Liu X; Zhou X J Control Release; 2023 Mar; 355():54-67. PubMed ID: 36693527 [TBL] [Abstract][Full Text] [Related]
13. Schistosoma japonicum soluble egg antigens induce apoptosis and inhibit activation of hepatic stellate cells: a possible molecular mechanism. Duan Y; Gu X; Zhu D; Sun W; Chen J; Feng J; Song K; Xu F; He X; He X Int J Parasitol; 2014 Mar; 44(3-4):217-24. PubMed ID: 24487000 [TBL] [Abstract][Full Text] [Related]
14. Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-associated mitochondrial apoptotic pathway. Sun Z; Guo Y; Xu X; Zhou C; Luo X; Shen Z; Shen B; Wang J; Lu J; Zhang Q; Shen F; Yu L; Ye Y; Zhang L; Luo Y; Qu Y; Cai X; Dong H; Lu L J Gastroenterol Hepatol; 2024 Aug; 39(8):1695-1703. PubMed ID: 38804845 [TBL] [Abstract][Full Text] [Related]
15. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL. Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928 [TBL] [Abstract][Full Text] [Related]
16. NLRC5 regulates TGF-β1-induced proliferation and activation of hepatic stellate cells during hepatic fibrosis. Xu T; Ni MM; Xing-Li ; Li XF; Meng XM; Huang C; Li J Int J Biochem Cell Biol; 2016 Jan; 70():92-104. PubMed ID: 26592197 [TBL] [Abstract][Full Text] [Related]
17. Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis. Bansal R; Prakash J; de Ruijter M; Beljaars L; Poelstra K Mol Pharm; 2011 Oct; 8(5):1899-909. PubMed ID: 21800888 [TBL] [Abstract][Full Text] [Related]
18. Smad2 increases the apoptosis of activated human hepatic stellate cells induced by TRAIL. Xu F; Zhou D; Meng X; Wang X; Liu C; Huang C; Li J; Zhang L Int Immunopharmacol; 2016 Mar; 32():76-86. PubMed ID: 26802603 [TBL] [Abstract][Full Text] [Related]
19. Activated hepatic stellate cell-derived Bmp-1 induces liver fibrosis via mediating hepatocyte epithelial-mesenchymal transition. Wan S; Liu X; Sun R; Liu H; Jiang J; Wu B Cell Death Dis; 2024 Jan; 15(1):41. PubMed ID: 38216590 [TBL] [Abstract][Full Text] [Related]
20. Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy. Lin Y; Yan M; Bai Z; Xie Y; Ren L; Wei J; Zhu D; Wang H; Liu Y; Luo J; Li X J Nanobiotechnology; 2022 Oct; 20(1):432. PubMed ID: 36183106 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]